Cargando…
Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies
Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failu...
Autores principales: | Perpinia, Anastasia Stella, Kadoglou, Nikolaos, Vardaka, Maria, Gkortzolidis, Georgios, Karavidas, Apostolos, Marinakis, Theodoros, Papachrysostomou, Chrysostomi, Makaronis, Panagiotis, Vlachou, Charikleia, Mantzourani, Marina, Farmakis, Dimitrios, Konstantopoulos, Konstantinos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412591/ https://www.ncbi.nlm.nih.gov/pubmed/36015155 http://dx.doi.org/10.3390/ph15081007 |
Ejemplares similares
-
Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis
por: Goulas, Kyriakos, et al.
Publicado: (2023) -
A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement
por: Papanastasiou, Labrini, et al.
Publicado: (2022) -
Cardiotoxicity of Novel Targeted Hematological Therapies
por: Giudice, Valentina, et al.
Publicado: (2020) -
Assessment and Management of Cardiotoxicity in Hematologic Malignancies
por: Bojan, Anca, et al.
Publicado: (2021) -
Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
por: Dong, Rong, et al.
Publicado: (2022)